EHA 2020 | BAY1436032: IDH1 inhibition in IDH1-mutated AML

Name: BAY1436032: IDH1 inhibition in IDH1-mutated AML
Uploaded: 2020-06-02T00:00:00Z
Duration: 3 min 1 s
Description: Michael Heuser, MD, of Hannover Medical School, Hannover, Germany, reports the Phase I safety and efficacy results of the mutant IDH1 inhibitor, BAY1436032 in subjects with IDH1-mutated acute myeloid leukemia (AML). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Michael Heuser • 2 Jun 2020

EHA 2020

Acute Myeloid Leukemia Leukemia BAY1436032

Michael Heuser, MD, of Hannover Medical School, Hannover, Germany, reports the Phase I safety and efficacy results of the mutant IDH1 inhibitor, BAY1436032 in subjects with IDH1-mutated acute myeloid leukemia (AML). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).